A ranar 6 ga Yuni, mujallar likitanci ta duniya Journal of Hematology & Oncology ta buga sakamakon binciken mataki na I/II (KL264-01/MK-2870-001) na sabuwar hanyar TROP2 ADC sacituzumab tirumotecan (sac-TMT) a matsayin maganin ciwon daji da ba a iya cirewa a cikin gida ba ko kuma wanda ya yi kama da wanda ba a iya magance shi ba, wanda ya saba wa magunguna na yau da kullun.
Sacituzumab tirumotecan (sac-TMT) wani haɗin maganin rigakafi ne wanda ya ƙunshi wani maganin rigakafi na monoclonal na anti-TROP2 wanda aka haɗa shi da wani maganin hana topoisomerase I na belotecan wanda aka samo daga cytotoxic (KL610023) ta hanyar sabon mahaɗi.
Hanyoyi
Marasa lafiya suna da ciwon daji mai ƙarfi wanda ba a iya cirewa a cikin gida/wanda ba a iya cirewa ba wanda ya saba da maganin gargajiya. A cikin rukunin masu karɓar allurai na mataki na 1, marasa lafiya suna da ciwon daji mai ƙarfi wanda ba a iya cirewa a cikin gida/wanda ba a iya cirewa ba wanda ya saba da maganin gargajiya. Ana ba da Sac-TMT ta hanyar allurar jijiya a kowane mako 2 a 2 zuwa 12 mg/kg. A mataki na 2, marasa lafiya da ke fama da cutar kansar nono ta TNBC da HR+/HER2− sun karɓi sac-TMT a kowace allurai da aka ba da shawarar don faɗaɗawa (RDEs) da aka gano a mataki na 1. Manyan manufofin sune tantance matsakaicin adadin da aka yarda da shi (MTD) na sac-TMT da kuma kafa RDEs (mataki na 1) da kuma tantance ORR ga kowane RECIST v1.1 ta hanyar kimantawa mai bincike (mataki na 2). An tantance abubuwan da suka faru marasa kyau bisa ga sigar NCI-CTCAE 5.0.
Sakamako
An yi wa marasa lafiya talatin rajista a mataki na 1 kuma an ba su sac-TMT 2 mg/kg (n = 4), 4 mg/kg (n = 7), 5 mg/kg (n = 7), 5.5 mg/kg (n = 5), da 6 mg/kg (n = 7). Marasa lafiya biyar suna da guba mai iyakance yawan shan magani: stomatitis na mataki na 3 a 4, 5.5, da 6 mg/kg; kurji na mataki na 3 a 5 mg/kg; da kuma urticaria na mataki na 3 a 6 mg/kg. MTD ya kasance 5.5 mg/kg kuma RDEs sun kasance 4 da 5 mg/kg. A cikin faɗaɗa allurai na mataki na 2, ORR (95% CI) ya kasance 34.8% (16.4%, 57.3%) a cikin rukunin 4-mg/kg (n = 23) da 38.9% (23.1%, 56.5%) a cikin rukunin 5-mg/kg (n = 36) don TNBC. ORR (95% CI) ya kasance 31.7% (18.1%, 48.1%) ga cutar kansar nono ta HR+/HER2− (n = 41).
Kammalawa
Sac-TMT ya nuna yanayin aminci mai kyau ga marasa lafiya da ke fama da ciwon daji na gida/wanda ba a iya magancewa ba, da kuma kyakkyawan aikin hana ciwon daji a cikin cutar kansar nono ta TNBC da HR+/HER2 −. Ana binciken Sac-TMT a cikin nazarin mataki na 3.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Lokacin Saƙo: Yuni-19-2025